Vol 48 No 7

July 28, 2020

"This new therapy could change the landscape for the treatment of advanced prostate cancer," Thrasher writes.

July 27, 2020

Oral GnRH receptor antagonist has “potential to become a new standard for ADT,” a study investigator says.

July 15, 2020

The study compared regimens for patients with high-risk non–muscle invasive bladder cancer.

July 14, 2020

Significant improvements in BPH-related lower urinary tract symptoms were observed with the system.

July 14, 2020

72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.

July 09, 2020

3 urologists discuss their experience with telemedicine during the COVID-19 pandemic.

July 08, 2020

Withdrawals from pretax retirement accounts are among the ways to bridge your income, according to Jeff Witz, CFP.

July 07, 2020

Samuel J. Peretsman, MD, discusses which patients with prostate cancer can be treated with HIFU, contraindications to the treatment, and what expectations patients need to have postoperatively.

July 07, 2020

Dr. Badar M. Mian highlights the safety and efficacy of relugolix, describing the drug as an “exciting new option” for patients with recurrent or advanced prostate cancer.

July 03, 2020

The decline in total testosterone was observed even among men with normal body mass index.

June 30, 2020

The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.

June 29, 2020

The deletion of code 99201 is among the evaluation/management coding changes for 2021.

June 23, 2020

Only 1.5% of patients undergo repeat surgical intervention for BPH recurrence.